Zentalis Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 3.59 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 3.59M shares, a 31.47% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 5.24M shares, a 199.26% increase from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.75M shares, a 25.24% increase from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.40M shares, a 711.67% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|
| 2025-12-31 | 3.59M shares 10-K · filed 2026-03-26 |
| 2024-12-31 | 5.24M shares 10-K · filed 2025-03-26 |
| 2023-12-31 | 1.75M shares 10-K · filed 2024-02-27 |
| 2022-12-31 | 1.40M shares 10-K · filed 2023-03-01 |
| 2021-12-31 | 172.35K shares 10-K · filed 2022-02-24 |
| 2020-12-31 | 16.52K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |